TY - JOUR
T1 - Perioperative aspirin management after POISE-2
T2 - Some answers, but questions remain
AU - Gerstein, Neal Stuart
AU - Carey, Michael Christopher
AU - Cigarroa, Joaquin E.
AU - Schulman, Peter M.
N1 - Publisher Copyright:
Copyright © 2015 International Anesthesia Research Society.
PY - 2015/3/4
Y1 - 2015/3/4
N2 - Aspirin constitutes important uninterrupted lifelong therapy for many patients with cardiovascular (CV) disease or significant (CV) risk factors. However, whether aspirin should be continued or withheld in patients undergoing noncardiac surgery is a common clinical conundrum that balances the potential of aspirin for decreasing thrombotic risk with its possibility for increasing perioperative blood loss. In this focused review, we describe the role of aspirin in treating and preventing cardiovascular disease, summarize the most important literature on the perioperative use of aspirin (including the recently published PeriOperative ISchemic Evaluation [POISE]-2 trial), and offer current recommendations for managing aspirin during the perioperative period. POISE-2 suggests that aspirin administration during the perioperative period does not change the risk of a cardiovascular event and may result in increased bleeding. However, these findings are tempered by a number of methodological issues related to the study. On the basis of currently available literature, including POISE-2, aspirin should not be administered to patients undergoing surgery unless there is a definitive guideline-based primary or secondary prevention indication. Aside from closed-space procedures, intramedullary spine surgery, or possibly prostate surgery, moderate-risk patients taking lifelong aspirin for a guideline-based primary or secondary indication may warrant continuation of their aspirin throughout the perioperative period.
AB - Aspirin constitutes important uninterrupted lifelong therapy for many patients with cardiovascular (CV) disease or significant (CV) risk factors. However, whether aspirin should be continued or withheld in patients undergoing noncardiac surgery is a common clinical conundrum that balances the potential of aspirin for decreasing thrombotic risk with its possibility for increasing perioperative blood loss. In this focused review, we describe the role of aspirin in treating and preventing cardiovascular disease, summarize the most important literature on the perioperative use of aspirin (including the recently published PeriOperative ISchemic Evaluation [POISE]-2 trial), and offer current recommendations for managing aspirin during the perioperative period. POISE-2 suggests that aspirin administration during the perioperative period does not change the risk of a cardiovascular event and may result in increased bleeding. However, these findings are tempered by a number of methodological issues related to the study. On the basis of currently available literature, including POISE-2, aspirin should not be administered to patients undergoing surgery unless there is a definitive guideline-based primary or secondary prevention indication. Aside from closed-space procedures, intramedullary spine surgery, or possibly prostate surgery, moderate-risk patients taking lifelong aspirin for a guideline-based primary or secondary indication may warrant continuation of their aspirin throughout the perioperative period.
UR - http://www.scopus.com/inward/record.url?scp=84927680004&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84927680004&partnerID=8YFLogxK
U2 - 10.1213/ANE.0000000000000589
DO - 10.1213/ANE.0000000000000589
M3 - Review article
C2 - 25695574
AN - SCOPUS:84927680004
SN - 0003-2999
VL - 120
SP - 570
EP - 575
JO - Anesthesia and analgesia
JF - Anesthesia and analgesia
IS - 3
ER -